The manufacturer of canakinumab (Novartis) was invited to submit evidence for this single technology appraisal in November 2013.

The manufacturer informed NICE that it had decided not to provide an evidence submission because it does not believe that sufficient data are available to inform a robust health technology assessment of canakinumab for the patients with systemic juvenile idiopathic arthritis who are likely to be considered for treatment in UK clinical practice.

NICE has therefore terminated this single technology appraisal.

  • National Institute for Health and Care Excellence (NICE)